Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Inclusion Criteria

• •MarketScan® secukinumab cohort:
• •Included patients with at least 1 secukinumab claim between 01 January 2015 and 30 June 2020 (index date is the first secukinumab claim)
• •Included patients age ≥18 years as of the year of index date
• •Included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period
• •Included patients with continuous medical/pharmacy coverage in the 2-year pre-index period
• •Included patients with continuous medical/pharmacy coverage in the 1-year post-index period
• •Included non-switched patients with secukinumab treatment on or after the enrollment between 01 January 2017 to 01 September 2020
• •* Non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date
• •* Index date will be the date of the first secukinumab treatment date
• •Included patients with age ≥ 18 on the index date
• •Included patients with psoriasis diagnosis in the pre-index period and index date
• •Included patients with ≥ 1 year follow-up period
• •* Follow-up period is the gap between patient's last visit date and index date